The Week in Review: October 6 – October 13, 2017

Friday, October 13, 2017 News Recap: Research & Discoveries After an intense hunt, researchers at the Norwegian University of Science and Technology (NTNU) can now describe an important part of the disease's guerrilla tactics: how hepatitis C converts innocent cells into outright virus factories.  How hepatitis C hides in the body. Apparently, liver cancer can be caught at an early stage through a newly developed blood test, improving the odd...

Drug Combo Efficacy Examined for Patients with HCV and Kidney Disease

HealthDay News — For patients with stage 4 or 5 chronic kidney disease and hepatitis C virus (HCV) infection, 12 weeks of treatment with glecaprevir and pibrentasvir [Maviret] results in a high rate of sustained virologic response, according to a study published online October 11 in the New England Journal of Medicine. The researchers found that the sustained virologic response rate was 98%. During treatment, none of the patients had virologic failure, an

Chronic Hepatitis C and Chronic Kidney Disease: Advances, Limitations and Unchartered Territories

It is well known that patients with chronic hepatitis C virus (HCV) infection have an increased risk of chronic kidney disease (CKD), regardless of whether they have additional risk factors for renal insufficiency. In a recent meta-analysis of nearly 3 million individuals where kidney function and HCV serological status were assessed, chronic HCV infection predicted a 51% increase in the risk of proteinuria and a 43% increase in the incidence of CKD. Back

The Week in Review: Nov 25 – Dec 2, 2016

Friday, December 2, 2016 News Recap Top of the news is that both Canada (Information Update – Direct-acting antivirals, used for hepatitis C, may reactivate hepatitis B) and Europe (EU health regulator warns some hep C drugs could reactivate hep B) are warning of the possibility of HBV reactivation from HCV DAA therapy.  The first warnings came out in April 2016 at EASL and then the US FDA issued warnings in October 2016. In a press release, Health C...

Hepatitis C Damage Doesn’t Stop at the Liver, Renal Failure Risk Seen

A new study of chronic kidney disease (CKD) patients shows untreated hepatitis C virus infection (HCV) leads to a more precipitous decrease in kidney function, a decline more likely to become end-stage renal disease (ERD) Reporting at IDWeek 2016 in New Orleans, LA, Sara Tartof, PhD, MPH, of the Kaiser Permanente Southern California (KPSC) Research & Evaluation Department in Pasadena, CA, and colleagues found CKD patients with untreated HCV were one a

AbbVie’s Investigational, Pan-Genotypic Regimen of Glecaprevir/Pibrentasvir (G/P) Shows High SVR Rates in Chronic Hepatitis C Patients with Severe Chronic Kidney Disease

- 98 percent of patients across all major HCV genotypes (GT1-6) with severe chronic kidney disease (CKD), including patients on dialysis, achieved SVR12 with 12 weeks of G/P in the primary intent-to-treat analysis, regardless of previous treatment status or presence of compensated cirrhosis - 100 percent of patients achieved SVR12 in a modified intent-to-treat analysis - G/P is an investigational, pan-genotypic, once-daily, ribavirin-free, fixed-dose com...